Randomized controlled clinical trial of Shenzhuo Formula in the treatment of macroalbuminuria in diabetic kidney disease and its inflammation-modulating mechanisms

Abstract

Background: Shenzhuo Formula (SZF), a modified Didang Tang, is used for diabetic kidney disease (DKD), though high-quality evidence is limited.

Methods: In a randomized, double-blind, double-dummy, active-controlled, multicenter trial, irbesartan (IRB) was the control. A Bayesian model assessed efficacy. Mechanistic studies included Olink inflammation proteomics, single-cell RNA sequencing (scRNA-seq) of KK-Ay mouse kidneys, and in vivo experiments.

Results: A total of 120 DKD patients with macroalbuminuria were randomized (SZF n = 57, IRB n = 63). At 24 weeks, 24 h urinary total protein change was −0.03 (−0.24 to 0.18) g/24 h in the SZF group and 0.08 (−0.30 to 0.14) g/24 h in the IRB group (P = 0.61). Estimated glomerular filtration rate improved with SZF by 5.91 (1.80 to 10.01) mL/min/1.73m² but declined with IRB by −1.67 (−5.18 to 1.84) mL/min/1.73m² (P < 0.01). Serum creatinine decreased with SZF by −5.15 (−9.73 to −0.56) μmol/L but increased with IRB by 3.39 (−0.84 to 7.61) μmol/L (P < 0.01). Traditional Chinese medicine syndrome response was higher with SZF (89.47% vs. 63.49%, P < 0.01). Safety and metabolic parameters were comparable. Bayesian analysis favored SZF for renal benefit. Mechanistically, SZF downregulated CX3CL1 in endothelial cells and MCP-1 in mesangial and tubular cells, suggesting anti-inflammatory effects restoring endothelial function and attenuating fibrosis.

Conclusions: SZF matched IRB in proteinuria reduction but was superior in preserving renal function and improving traditional Chinese medicine symptoms in DKD, with good safety. Benefits may involve suppression of CX3CL1/MCP-1-mediated inflammation.

Keywords

diabetic kidney disease / traditional Chinese medicine / Shenzhuo Formula / macroalbuminuria

Acknowledgements

This work was supported by the Noncommunicable Chronic Diseases-National Science and Technology Major Project (grantNo. 2023ZD0509300), the National Natural Science Foundation of China (grant No. 82505276) and the Clinical Research Fund of the Central High-level Hospital of Traditional Chinese Medicine (grant No. HLCMHPP2023084). Also, we would like to thank the researchers and study participants for their contributions.

Author contributions

Anzhu Wang (Conceptualization, Formal Analysis, Visualization, Writing—original draft), Yishan Huang (Investigation), Yu Wei (Investigation), lili Zhang (Investigation), Hongdong Chen (Data curation), Xiaoqing Wang (Investigation), Zhimei Cui (Investigation), Bin Wang (Investigation), Wei Liu (Investigation), Chao Chen (Investigation), Ye Lei (Investigation), Zhonghua Zheng (Investigation), Yan Wei (Investigation), Jia Mi (Investigation), Keda Lu (Investigation), Ying Zhang (Methodology), Linhua Zhao (Conceptualization, Funding acquisition, Project administration, Writing—review & editing), and Xiaolin Tong (Conceptualization, Funding acquisition, Supervision).

Supplementary data

Supplementary data is available at PCMEDI Journal online.

Conflict of interest

None declared.

Notes

Trial registration: Chinese Clinical Trial Registry ChiCTR-ICR-15006311

References

[1] Zhang H, Jia Q, Song P et al. Incidence, prevalence, and burden of type 2 diabetes in China: Trend and projection from 1990 to 2050. Chin Med J (Engl) 2025;138:1447-55. https://doi.org/10.1097/CM9.0000000000003536

[2] Sun H, Saeedi P, Karuranga S et al. IDF Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. Diabetes Res Clin Pract 2022;183:109119. https://doi.org/10.1016/j.diabres.2021.109119

[3] de Boer IH, Rue TC, Hall YN et al. Temporal trends in the prevalence of diabetic kidney disease in the United States. JAMA 2011;305:2532-9. https://doi.org/10.1001/jama.2011.861

[4] Afkarian M, Zelnick LR, Hall YN et al. Clinical manifestations of kidney disease among US adults with diabetes, 1988-2014. JAMA 2016;316:602-10. https://doi.org/10.1001/jama.2016.10924

[5] Ruiz-Ortega M, Rodrigues-Diez RR, Lavoz C et al. Special Issue "Diabetic Nephropathy: Diagnosis, Prevention and Treatment". JCM 2020;9:813. https://doi.org/10.3390/jcm9030813

[6] Expert Committee on Diabetic Kidney Disease ESCotCAoIM, and Traditional Chinese Medicine and Microcirculation Specialty Committee of the Chinese Microcirculation Society. Expert consensus on the prevention and treatment of diabetic kidney disease with the integrated traditional Chinese and Western medicine (2023 edition). Chin J Diabetes 2023;15:690-702. https://doi.org/10.3760/cma.j.cn115791-20230523-00216

[7] Brenner BM, Cooper ME, de Zeeuw D et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001;345:861-9. https://doi.org/10.1056/NEJMoa011161

[8] de Zeeuw D, Remuzzi G, Parving HH et al. Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL. Kidney Int 2004;65:2309-20. https://doi.org/10.1111/j.1523-1755.2004.00653.x

[9] Association EGotNBotCM. Chinese guidelines for diagnosis and treatment of diabetic kidney disease. Chin J Nephrol 2021;37:255-304.https://doi.org/10.3760/cma.j.cn441217-20201125-00041

[10] Yuan XH, Huang YH. Ancient literature review of herba medicine administered to diabetes nephropathy. Tianjin J Tradit Chin Med 2017;34:159-62.

[11] Wen Y, Yan M, Zhang B et al. Chinese medicine for diabetic kidney disease in China. Nephrology 2017;22:50-5. https://doi.org/10.1111/nep.13149

[12] Ren QY, Chang B. Prospective study on modified Shuilu Erxian Pills and Didang Decoction in the treatment of early diabetic nephropathy. West J Tradit Chin Med 2021;34:9-12.

[13] Tian JX, Zhao LH, Zhou Q et al. Retrospective analysis on modified Didang Tang for treating microalbuminuria of diabetic nephropathy. Mod Chin Clin Med 2012;19:7-10.

[14] Wu MJ, Peng L Treating 31 cases of diabetic nephropathy with Jiawei Dingdang decoction. Hunan J Tradit Chin Med 2011;27:57-8.

[15] Yu ZX, Zhang WJ, Zhou LN et al. A clinical study of integrated Chinese and Western medicine treatment to 32 cases of Qi deficiency and blood stasis type of DN at the 3rd stage. Jiangsu J Tradit Chin Med 2019;51:30-2.

[16] Zhang YY, Huang HQ. Study of improving prescription of Didang decoction on diabetic nephropathy in earlier period. Mod J Integr Tradit Chin West Med 2002;11:2091-2.

[17] Chen H, Guo J, Zhao X et al. Retrospective analysis of the overt proteinuria diabetic kidney disease in the treatment of modified Shenzhuo formula for 2 years. Medicine (Baltimore) 2017;96:e6349. https://doi.org/10.1097/MD.0000000000006349

[18] Tian J, Zhao L, Zhou Q et al. Efficacy of Shenzhuo formula on diabetic kidney disease: a retrospective study. J Tradit Chin Med 2015;35:528-36. https://doi.org/10.1016/s0254-6272(15)30135-7

[19] Rayego-Mateos S, Rodrigues-Diez RR, Fernandez-Fernandez B et al. Targeting inflammation to treat diabetic kidney disease: the road to 2030. Kidney Int 2023;103:282-96. https://doi.org/10.1016/j.kint.2022.10.030

[20] Wei Y, Huang YS, Yang Z et al. Effectiveness of the Shenzhuo formula in the treatment of patients with macroalbuminuria secondary to diabetic kidney disease: protocol update and statistical analysis plan. Trials 2022;23:61. https://doi.org/10.1186/s13063-021-05961-8

[21] Zhao XM, Zhang Y, He XH et al. Chinese herbal medicine Shenzhuo Formula treatment in patients with macroalbuminuria secondary to diabetic kidney disease: study protocol for a randomized controlled trial. Trials 2018;19:200. https://doi.org/10.1186/s13063-018-2573-z

[22] World Medical Association. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA 2013;310:2191-4. https://doi.org/10.1001/jama.2013.281053

[23] Chan AW, Tetzlaff JM, Gotzsche PC et al. SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials. BMJ 2013;346:e7586. https://doi.org/10.1136/bmj.e7586

[24] Drouin P, Blickle JF, Charbonnel B et al. Diagnosis and classification of diabetes mellitus: the new criteria. Diabetes Metab 1999;25:72-83

[25] American Diabetes Association. Standards of medical care in diabetes—2013. Diabetes Care 2013;36:S11-66. https://doi.org/10.2337/dc13-S011

[26] National Kidney Foundation. KDOQI clinical practice guideline for diabetes and CKD: 2012 update. Am J Kidney Dis 2012;60:85086. https://doi.org/10.1053/j.ajkd.2012.07.005

[27] Zheng XY. Guidelines for Clinical Research on New Chinese Medicines (Trial Edition). China Medical Science and Technology Press: Beijing, 2002.

[28] Tong XL. Clinical Evidence-Based Practice Guidelines for Traditional Chinese Medicine in Diabetes (2016 Edition). Science Press: Beijing, 2016.

[29] Wang A, Li Z, Sun Z et al. Heart failure with preserved ejection fraction and non-alcoholic fatty liver disease: new insights from bioinformatics. ESC Heart Fail 2023;10:416-31. https://doi.org/10.1002/ehf2.14211

[30] Gao Z, Zhang W, He L et al. Double-blinded, randomized clinical trial of Gegen Qinlian decoction pinpoints Faecalibacterium as key gut bacteria in alleviating hyperglycemia. Precis Clin Med 2024;7:pbae003. https://doi.org/10.1093/pcmedi/pbae003

[31] 31 Zhang L, Shergis JL, Yang L et al. Astragalus membranaceus (Huang Qi) as adjunctive therapy for diabetic kidney disease: An updated systematic review and meta-analysis. J Ethnopharmacol 2019;239:111921. https://doi.org/10.1016/j.jep.2019.111921

[32] Shen Q, Fang J, Guo H et al. Astragaloside IV attenuates podocyte apoptosis through ameliorating mitochondrial dysfunction by up-regulated Nrf2-ARE/TFAM signaling in diabetic kidney disease. Free Radical Biol Med 2023;203:45-57. https://doi.org/10.1016/j.freeradbiomed.2023.03.022

[33] Huang Y, Wu SM, Zhao L. A systematic review of the efficacy of Rhubarb in the treatment of diabetic kidney disease. Heilongjiang J Tradit Chin Med 2021;50:86-9.

[34] Xiong D, Hu W, Han X et al. Rhein inhibited ferroptosis and EMT to attenuate diabetic nephropathy by regulating the Rac1/NOX1/beta-Catenin axis. Front Biosci (Landmark Ed) 2023;28:100. https://doi.org/10.31083/j.fbl2805100

[35] Xu Q Wen H, Li XS et al. Efficacy of Tanshinone IIA sulfonate sodium for treatment of diabetic nephropathy: A meta-analysis of randomizedclinical trials. Tradit Chin Drug Res Clin Pharmacol 2020;31:113-9.

[36] Xu Z, Cai K, Su SL et al. Salvianolic acid B and tanshinone IIA synergistically improve early diabetic nephropathy through regulating PI3K/Akt/NF-kappaB signaling pathway. J Ethnopharmacol 2024;319:117356. https://doi.org/10.1016/j.jep.2023.117356

[37] Shen Z, Cui T, Liu Y et al. Astragalus membranaceus and Salvia miltiorrhiza ameliorate diabetic kidney disease via the "gutkidney axis". Phytomedicine 2023;121:155129. https://doi.org/10.1016/j.phymed.2023.155129

[38] Liu JY, Xu SS, Zeng HW et al. Meta-analysis of efficacy and safety of leech on diabetic nephropathy. J Pract Tradit Chin Intern Med 2021;35:137-139+157.

[39] Yang F, Cao C, Fang J et al. Protective effects of hirudo lyophilized powder on renal injury in diabetic nephropathy rats. Chin Tradit Herb Drugs 2021;52: 1020-5.

[40] Wang K, Zheng X, Pan Z et al. Icariin prevents extracellular matrix accumulation and ameliorates experimental diabetic kidney disease by inhibiting oxidative stress via GPER mediated p62-dependent Keap 1 degradation and Nrf2 activation. Front Cell Dev Biol 2020;8: 559. https://doi.org/10.3389/fcell.2020.00559

[41] Cheng H, Bo Y, Shen W et al. Leonurine ameliorates kidney fibrosis via suppressing TGF-beta and NF-kappaB signaling pathway in UUO mice. Int Immunopharmacol 2015;25:406-15. https://doi.org/10.1016/j.intimp.2015.02.023

[42] Hemmelgarn BR, Zhang J, Manns BJ et al. Progression of kidney dysfunction in the community-dwelling elderly. Kidney Int 2006;69:2155-61. https://doi.org/10.1038/sj.ki.5000270

[43] Parving HH, Lambers-Heerspink H, de Zeeuw D. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med 2016;375:1799-802. https://doi.org/10.1056/NEJMc1611290

[44] Ji Q, Luo YQ, Wang WH et al. Research advances in traditional Chinese medicine syndromes in cancer patients. Journal of Integrative Medicine 2016;14:12-21. https://doi.org/10.1016/S2095-4964(16)60237-6

[45] Helou N, Talhouedec D, Zumstein-Shaha M et al. A multidisciplinary approach for improving quality of life and selfmanagement in diabetic kidney disease: A crossover study. JCM 2020;9:2160. https://doi.org/10.3390/jcm9072160

[46] Hu Y, Tang W, Liu W et al. Astragaloside IV alleviates renal tubular epithelial-mesenchymal transition via CX3CL1RAF/MEK/ERK signaling pathway in diabetic kidney disease. Drug Des Devel Ther 2022;16:1605-20.https://doi.org/10.2147/DDDT.S360346

[47] Yu J, Da J, Yu F et al. HMGN1 down-regulation in the diabetic kidney attenuates tubular cells injury and protects against renal inflammation via suppressing MCP-1 and KIM-1 expression through TLR4. J Endocrinol Invest 2024;47:1015-27. https://doi.org/10.1007/s40618-023-02292-0

[48] Yi L, Liang Y, Zhao Q et al. CX3CL 1 induces vertebral microvascular barrier dysfunction via the Src/P115-RhoGEF/ROCK signaling pathway. Front Cell Neurosci 2020;14:96. https://doi.org/10.3389/fncel.2020.00096

[49] Penrose HM, Katsurada A, Miyata K et al. STAT1 regulates interferon-gamma-induced angiotensinogen and MCP 1 expression in a bidirectional manner in primary cultured mesangial cells. J Renin Angiotensin Aldosterone Syst 2020;21:1470320320946527. https://doi.org/10.1177/1470320320946527

[50] Borza CM, Bolas G, Bock F et al. DDR1 contributes to kidney inflammation and fibrosis by promoting the phosphorylation of BCR and STAT3. JCI Insight 2022;7:e150887. https://doi.org/10.1172/jci.insight.150887

[51] Wang N, Zhang C. Recent advances in the management of diabetic kidney disease: Slowing progression. Int J Mol Sci 2024;25:3086. https://doi.org/10.3390/ijms25063086

[52] Sou YL, Chilian WM, Ratnam W et al. Exosomal miRNAs and isomiRs: potential biomarkers for type 2 diabetes mellitus. Precis Clin Med 2024;7:pbae021. https://doi.org/10.1093/pcmedi/pbae021